Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer CorpfiledCriticalBayer Corp
Publication of AR027764A1publicationCriticalpatent/AR027764A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La BTL-012 es una nueva proteína humana util para regular o modular la angiogénesis. La BTL-012, o sus variantes, pueden emplearse como terapia enenfermedades como el cáncer, la curacion de heridas, las retinopatías diabéticas, la degeneracion macula r, y las enfermedades cardiovasculares y otrasenfermedades o condiciones clínicas en las cuales la angiogénesis es relevante a la causa o el tratamiento de la enfermedad.BTL-012 is a new human protein useful for regulating or modulating angiogenesis. BTL-012, or its variants, can be used as therapy in diseases such as cancer, wound healing, diabetic retinopathies, macular degeneration r, and cardiovascular diseases and other diseases or clinical conditions in which angiogenesis is relevant to cause or treatment of the disease.
ARP010101581A2000-03-312001-04-03
PROTEINS THAT HAVE ACTIVITY AS AN ANGIOGENESIS MODULATOR
AR027764A1
(en)
5,6,7-TRIHYDROXYPHEPTANIC ACIDS AND ANALOGS FOR THE TREATMENT OF EYE DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVES AND ANGIOGENIC REACTIONS